PharmaTelevision - BIOTECanada: Peter Brenders. Canada's brain gain and exciting things happening with Canadian biotechnology companies.

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: BIOTECanada: Peter Brenders. Canada's brain gain and exciting things happening with Canadian biotechnology companies.

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Peter Brenders, President and CEO of BIOTECanada.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Peter Brenders's perspective: Current biotech environment in Canada

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BIO-Europe, in Duesseldorf in 2011. On this show I have Peter Brenders, who is President and CEO of BIOTECanada which is based in Ottawa, in Canada of course, welcome.

Peter Brenders:

Thank you.

Fintan Walton:

Peter, obviously BIOTECanada most people will know as the leading Canadian organization that promotes biotech and is an advocate for biotech particularly in lobbying the Canadian government but has a general interest in seeing the biotech industry grow and attract outside investment as well, so could you describe to us, how would you describe the current biotech environment in Canada?

Peter Brenders:

Good question, it's certainly coming out of a long winter difficult financing what we've seen out there, I think biotech in Canada is on a tremendous rebound, exciting things happening with Canadian biotechnology companies today. We've seen over the last two months probably some $300 million in deals and deal flow that's happening into Canada's biotech community from large to small companies are interested in Canadian technology.

Fintan Walton:

So when you talk about deal flow you are talking about equity financing as well as licensing and collaborative type of deals?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Peter Brenders

President

At the time of recording this PTV interview Peter Brenders President and CEO of BIOTECanada . Peter Brenders joined BIOTECanada as President & CEO in February 2005. Previously, he worked in health and corporate affairs in senior management roles at Genzyme Canada and Schering-Plough Canada. Mr. Brenders has also worked in the Ontario Ministry of Health and in the health consulting practice at KPMG. Mr. Brenders is currently a member of the Advisory Board for the National Research Council's (NRC) Institute for Marine Biosciences and the NRC's Institute for Nutrisciences and Health, a member of the Department of Foreign Affairs and International Trade's Life Sciences Advisory Board and the Industry Advisor for the Atlantic Canada Opportunity Agency's Atlantic Innovation Fund Committees for Aquaculture and Biotechnology Sector and Health and Medical Sector. He is a member of the Advisory Council for Algonquin College's biotechnology program, and has served as a member of the Privy Council Office's Reference Group on Regulating, as a Board member and Treasurer of the Registered Nurses Association of Ontario Foundation, and has served as the Chair of its Toronto Chapter of the Canadian College of Health Services Executives. Mr. Brenders received his MBA, in Health Services Management from McMaster University. Prior to his brief work in basic research at the Robarts Research Institute, he received his Honours BSc in Pharmacology and Toxicology from the University of Western Ontario.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

BIOTECanada

BIOTECanada: Incorporated in 1987 as the Industrial Biotechnology Association of Canada, BIOTECanada serves as the national voice for industry leadership for Canada's biotechnology sector. Through national network of partner organizations inspires domestic and international community to recognize the value of biotechnology and to provide solutions to the challenges faced by biotech firms today. BIOTECanada is dedicated to the sustainable commercial development of biotechnology innovation in Canada. It is the national industry-funded association with over 250 member companies representing the broad spectrum of biotech constituents including emerging and established firms in the health, industrial, and agricultural sectors, as well as academic and research institutions and other related organizations. BIOTECanada has the goal to inspire domestic and international community to recognize the value of biotechnology in Canada and provide solutions to the challenges that constituents face.